Ann: Notices received under s203D and s249D of Corporations Act, page-33

I've had the same question since the topline announcement - what are the Lymphocyte Counts / CD49d results?

I originally thought the following highlighted section of the topline announcement referred to the quality-of-life assessment.

I'm now thinking this point is referring to the Lymphocyte Counts / CD49d results. The Phase II announcement from December 2019 included a table of statistics with comments referring to trending significantly lower.

The ongoing administration of the drug over the 24 weeks you would expect to see a trend form for lower Lymphocyte Counts / CD49d. But the recent topline announcement indicates no trend.

Agree, more to this story.